MAY 0 8 2003

DADEMO

MODIFIED PTO/SB/08 (08-00)

Appr. ed for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no opersons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: May 6, 2003

(use as many sheets as necessary)

of 4 Sheet

C mplete if Known					
09/727,892	7/				
11/30/2000					
Jerry Pelletier	The Man				
1645	Ch				
V. Portner	Ch				
073406-0302					
	09/727,892 11/30/2000 Jerry Pelletier 1645 V. Portner				

	U.S. PATENT DOCUMENTS						
			U.S. Patent I	Document		Date of Publication of	Pages, Columns, Lines Where Relevant
Examiner Initials*	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
			_				
ļ.,							

		FC	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
1/20	A1	WO 99/37661	O'DONNELL, Michael E.			
	A2	WO 00/32825	PELLETIER, Jerry			
						-
						<del>                                     </del>
		·				

Examiner Signature	700	Date Considered	7/0-3	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

A mark and for upon the

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB ontrol number.

MAY 0 8 2003

TRADEWY

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: May 6, 2003

(use as many sheets as necessary)

2

Sheet

of

4

			<del>%) -</del>
		NON PATENT LITERATURE DOCUMENTS	<del></del>
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т <sup>6</sup>
180	A3	ADELMAN, John P., et al., "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone," DNA, 2(3):183-193 (1983).	
	A4	ALONSO, J. C. and FISHER, L. M., "Nucleotide Sequence of the recF Gene Cluster From Staphylococcus Aureus and Complementation Analysis in Bacillus Subtilis recF Mutants," <i>Mol. Gen. Genet.</i> , 248:680-686 (1995).	
	A5	ALTSCHUL, Stephen F., et al. "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs," <i>Nucleic Acids Research</i> , <u>25</u> (17):3389-3402 (1997).	
	A6	BARNES, Marjorie H. and BROWN, Neal C., "Purification of DNA Polymerase III of Gram-Positive Bacteria," <i>Methods In Enzymology</i> , 262:35-42 (1995).	
	A7	BRUCK, Irina and O'DONNELL, Mike, "The DNA Replication Machine of a Gram-positive Organism," <i>The Journal of Biological Chemistry</i> , 275(37):28971-28983 (2000).	
	A8	COLIGAN, John E., et al., "Production of Monoclonal Antibodies," <i>Current Protocols in Immunology</i> , 1(2):Chapter 5 (1991).	
	A9	COHEN, Mitchell L., "Epidemiology of Drug Resistance: Implications for a Post-Antimicrobial Era," <i>Science</i> , <u>257</u> :1050-1055 (1992).	
	A10	DE ANGELIS, Dino A., "Why FRET Over Genomics," Physiological <i>Genomics</i> , <u>1</u> :93-99 (1999).	
	A11	DREWS, Jürgen, "Drug Discovery: A Historical Perspective," Science, 287:1960-1964 (2000).	
	A12	DURFEE, Tim, et al., "The Retinoblastoma Protein Associates With the Protein Phosphatase Type 1 Catalytic Subunit," <i>Genes &amp; Dev., 7</i> :555-569 (1993).	
	A13	ENDO, Takaho, et al., "A New Protein Containing An SH2 Domain That Inhibits JAK Kinases," <i>Nature</i> , 387:921-924 (1997).	
	A14	FIELD, Jeffrey, et al., "Purification Of A RAS-Responsive Adenylyl Cyclase Complex From Saccharomyces cerevisiae By Use Of An Epitope Addition Method," Mol. Cell. Biol., 8:2159-2165 (1988).	3 .
	A15	KARIMOVA, Gouzel, et al., "A Bacterial Two-Hybrid System Based On A Reconstituted Signal Transduction Pathway," <i>Proc. Natl. Acad. Sci.</i> , 95:5752-5756 (1998).	n

Examiner	<u> </u>	0-1-	Date	_/_
Signature		09/10	Considered	//85

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

MAY 0 8 2003

TRADEM

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: May 6, 2003

(use as many sheets as necessary)
Sheet 3 of 4

	C mplete if Known	
Application Numb r	09/727,892	18 1/2 C
Filing Dat	11/30/2000	C/y 1
First Named Inv ntor	Jerry Pelletier	Ch. 12
Group Art Unit	1645	1/2 20
Examiner Name	V. Portner	<b>70</b> %
Attorney Docket Number	073406-0302	600

he article (when appropriate), title of the	
.) date, page(s), volume-issue number(s), re published.	T <sup>6</sup>
Interacting With DNA Repair Protein	
re And Function Of A Chromosomal	
toxin Structural Gene Is Not Detectably	
es," Pept. Res., <u>4(</u> 3):142-146 (1991).	
unction Of Antisense RNA In Its 66(2):560-567 (1991).	
d Catabolite Repression Of The Lactose 812 (1991).	
Identification," Anal. Chem., <u>69</u> (19):3995-	
ches With Multiple Intermediates To Detect	
For Electroporation of Staphylococcus	·
fammalian RNA Polymerase II," <i>J. Biol.</i>	
ri ri	ctor 2 Kinase GCN2 Is Mediated By The Protein Kinase Domain," Mol. Cell. Biol., rches With Multiple Intermediates To Detect .  For Electroporation of Staphylococcus  Mammalian RNA Polymerase II," J. Biol.

Examiner Signature	26Pd	Date Considered	7/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MAY 0 8 2003

CAULMY

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required respond to a collection of information unless it contains a valid OMB company

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: May 6, 2003

(use as many sheets as necessary)

Sheet

	Complete if Known	12	4	.C
Application Number	09/727,892	4	7/	~
Filing Date	11/30/2000		<u> </u>	
First Nam d Inv nt r	Jerry Pelletier		1/2	.در
Group Art Unit	1645		<b>7</b> %	10
Examiner Name	V. Portner		10	-5
Attorney Docket Number	073406-0302		O)	5

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>		
B	A27	SWANSTROM, M. and ADAMS, M. H., "Agar Layer Method For Production Of High Titer Phage Stocks," <i>Proc. Soc. Exptl. Biol. &amp; Med.</i> , <u>78</u> :372-375 (1951).			
	A28	TAURIAINEN, Sisko, et al., "Recombinant Luminescent Bacteria For Measuring Bioavailable Arsenite And Antimonite," <i>Appl. Environ. Microbiol.</i> , <u>63</u> (11):4456-4461 (1997).			

Examiner Signature	M	Date Considered	1/03

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2See attached Kinds of U.S. Patent Documents. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.